Ronocit 500 mg (20 tablets)

The instruction for medical use of Ronocit Torgovoye medicine a name of Ronocit the International unlicensed name Tsitikolin Lekarstvennaya the Tablet form, film coated 250 and 500 mg Structure One tablet contains active agent - a tsitikolin of sodium 261.258 and 522.516 of mg (250 and 500 mg of a tsitikolin are equivalent) excipients: starch corn, talc, hydroxypropyl cellulose, cellulose microcrystalline, kroskarmelloza sodium, silicon dioxide colloidal anhydrous, magnesium stearate structure of a cover: Опадри® II white 85F18422 (the polyvinyl alcohol which is partially hydrolyzed the titan dioxide (E 171), a macrogoal, talc) the Description of the Tablet of round shape, with a biconvex surface, film coated white color (with dosages of 250 and 500 mg) Pharmacotherapeutic group of Psikhoanaleptiki. Psychostimulants and nootropa. Psychostimulants and nootropa others. Tsitikolin ATH N06BX06 Code the Pharmacological Pharmacokinetics Tsitikolin properties is natural compound which contains in an organism. It is completely soaked up in digestive tract, & lt, 1% of a dose is revealed in Calais for 5 days after reception. Removal from an organism happens very slowly, mainly through respiratory organs and to urine. A pharmacodynamics Tsitikolin, being a predecessor of key ultrastructural components of a cellular membrane (mainly phospholipids), possesses a broad spectrum of activity - promotes restoration of the damaged cell membranes, inhibits action of phospholipases, interfering with excess education of free radicals and also prevents death of cells, influencing apoptosis mechanisms. In an acute period of a stroke reduces the volume of the damaged fabric, improves cholinergic transfer. In a craniocereberal injury reduces duration of a posttraumatic coma and expressiveness of neurologic symptoms. In case of a chronic hypoxia of a brain of Ronocit it is effective at treatment of such cognitive disorders as a memory impairment, lack of initiative, difficulties arising during the performing of daily actions and self-service. Perhaps long-term treatment by drug as tsitikolin does not influence breath, pulse and arterial blood pressure Indications - a stroke and its consequences - a craniocereberal injury and its consequences - the cognitive, sensitive and motive neurologic disorders caused by degenerative changes and vascular disorders. The route of administration and doses take the Drug inside. The recommended dose makes from 500 mg to 2000 mg a day. Doses of drug and duration of treatment depend on weight of damage of a brain and are established by the doctor. Patients of advanced age do not need dose adjustment Side effects Very seldom (& lt, 1/10.000) (including individual reactions). - allergic reactions, a small tortoiseshell, a dieback, erubescence up to purple coloring, a skin itching, hypostases, development of an acute anaphylaxis - a headache, dizziness, hallucinations, excitement, insomnia, temperature increase, feeling of heat, a tremor - dispnoe - nausea, vomiting, diarrhea - increase or short-term lowering of arterial pressure of the Contraindication - hypersensitivity to drug components - a vagotonia (prevalence of a tone of a parasympathetic part of the autonomic nervous system) is possible - children's age up to 6 years Medicinal interactions Tsitikolin enhances effects of a levodopa. It is not necessary to appoint drug along with the medicines containing Meclofenoxatum. Ronocit it is possible to apply at the same time with styptic means, intracranial antihypertensive drugs and with usual perfused liquids. The special instructions Use in pediatrics In children's practice appoint medicine if the expected therapeutic advantage exceeds possible risk. The age and the mode of dosing is defined by the attending physician individually. Pregnancy and the period of a lactation Though proofs of risk at use of drug during pregnancy or in the period of a lactation were not received, drug is appointed if the expected advantage exceeds potential risk for a fruit and the child. The feature of influence of medicine on ability to run the vehicle or potentially dangerous Tsitikolin mechanisms does not influence ability to control of vehicles and use of mechanisms. Overdose Cases of overdose are not described in connection with hypotoxicity of the drug Release Form and packing On 10 tablets place in blister strip packagings from aluminum foil. On 1 and/or 2 planimetric packs together with the instruction for medical use in the state and Russian languages put in a pack cardboard. To Store storage conditions at a temperature not above 25 °C. To store out of children's reach! A period of storage 3 years not to apply after an expiration date Prescription status According to the prescription Ilach San Uorld Meditsin Producer. ve Tidzh. A.Sh. (World Medicine İlaç San. ve Tic. A.Ş.), Istanbul, Turkey the Owner of the registration certificate of World Medicine Ltd, Tbilisi, Georgia the Name, the address and a contact information of the organization in the territory of the Republic of Kazakhstan, the accepting claim (offer) on quality of medicines from consumers of RIN Pharm LLP, Almaty, Turksibsky district, Suyunbaya Ave., 222b ph. / fax: 8 (727) 252 90 90 The name, the address and a contact information of the organization in the territory of the Republic of Kazakhstan responsible for post-registration observation of safety of medicine of TROKA-S PHARMA LLP, Almaty, Suyunbaya Avenue 222-b mobile phone number +7 701 786 33 98, (24-hour access). e-mail: pvpharma@worldmedicine.kz